1. In Vivo
  2. >>Business Strategy

European Companies Are Now Being ‘Properly Funded’

Silicon Valley Bank Managing Director Discusses Performance Of European Life Sciences In 2019

 
• By Lucie Ellis-Taitt

In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared to the $686m companies raised in 2018 overall. Silicon Valley Bank expects the European sector to be in “rude health” for the next two to three years at least, when it comes to accessing VC cash.

Euro_Silhouette
"Recently we have seen some record-level funds being raised in Europe" • Source: Shutterstock

Nooman Haque, managing director of life sciences and health care at Silicon Valley Bank’s UK branch, told In Vivo that Europe was still a positive environment for life science fund raising. “The money being raised by venture capital funds is an important predictor of how the financial environment will be for companies in the coming months. If a fund is raising £300m or so, that means over the next two to three years we have visibility that shows the sector will be in rude health and that money will be available.” He added that several European groups had been able to raise new funds recently, such as Forbion and LSP.

“More recently we have seen some record-level funds being raised, as well as some new funds under new managers,” Haque...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy